A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Wang, Eunice S ^a   Lyons, Roger M ^b   Larson, Richard A ^c   Gandhi, Sunil ^d   Liu, Delong ^e   Matei, Carmen ^f   Scott, Bart ^g   Hu, Kuolung ^h   Yang, Allen S ^h  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d Cancer and Blood Disease Center   (United States)

^e WESTCHESTER MEDICAL CENTER   (United States)

^f ROCKY MOUNTAIN CANCER CENTERS   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h AMGEN INC   (United States)

Author keywords

Lenalidomide; Myelodysplastic syndrome; Romiplostim; Thrombocytopenia

Indexed keywords

LENALIDOMIDE; PLACEBO; ROMIPLOSTIM;

ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; BONE MARROW; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERKALEMIA; INCIDENCE; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PLACEBOS; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; THALIDOMIDE; THROMBOPOIETIN;

EID: 84870064401     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-71     Document Type: Article

References (28)

1. Myelodysplastic syndromes. Tefferi A, Vardiman JW, N Engl J Med 2009 361 19 1872 1885 10.1056/NEJMra0902908 19890130
2. Myelodysplastic syndrome. Hofmann WK, Koeffler HP, Annu Rev Med 2005 56 1 16 10.1146/annurev.med.56.082103.104704 15660498
3. Myelodysplasia. Dansey R, Curr Opin Oncol 2000 12 1 13 21 10.1097/00001622-200001000-00003 10687724
4. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Cogle CR, Craig BM, Rollison DE, List AF, Blood 2011 117 26 7121 7125 10.1182/blood-2011-02- 337964 21531980
5. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, Laouri M, J Clin Oncol 2010 28 17 2847 2852 10.1200/JCO.2009.25.2395 20421543
6. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, Deuson R, Leveque J, Cancer 2007 109 9 1705 1714 10.1002/cncr.22602 17366593
7. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. Neukirchen J, Blum S, Kuendgen A, Strupp C, Aivado M, Haas R, Aul C, Gattermann N, Germing U, Eur J Haematol 2009 83 5 477 482 10.1111/j.1600-0609.2009.01299.x 19548919
8. A prognostic score for patients with lower risk myelodysplastic syndrome. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, et al. Leukemia 2008 22 3 538 543 10.1038/sj.leu.2405070 18079733
9. Myelodysplastic syndromes: biology and treatment. Jadersten M, Hellstrom-Lindberg E, J Intern Med 2009 265 3 307 328 10.1111/j.1365-2796.2008. 02052.x 19141095
10. Van-den Berghe's 5q- syndrome in 2008. Mohamedali A, Mufti GJ, Br J Haematol 2009 144 2 157 168 10.1111/j.1365-2141.2008.07447.x 19016715
11. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, Kundgen A, Lubbert M, Kunzmann R, Giagounidis AA, et al. Blood 2007 110 13 4385 4395 10.1182/blood-2007-03-082404 17726160
12. REVLIMID(R), (Lenalidomide) Capsules, for Oral Use [Prescribing Information] CA: Celgene Corporation, San Diego May 2012 http://www.revlimid. com/pdf/REVLIMID-PI.pdf
13. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, et al. N Engl J Med 2006 355 14 1456 1465 10.1056/NEJMoa061292 17021321
14. Efficacy of lenalidomide in myelodysplastic syndromes. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB, N Engl J Med 2005 352 6 549 557 10.1056/NEJMoa041668 15703420
15. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Canizo C, et al. Blood 2011 118 14 3765 3776 10.1182/blood-2011-01-330126 21753188
16. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, Raza A, List AF, J Clin Oncol 2008 26 36 5943 5949 10.1200/JCO.2007.15.5770 19018091
17. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Wang B, Nichol JL, Sullivan JT, Clin Pharmacol Ther 2004 76 6 628 638 10.1016/j.clpt.2004.08.010 15592334
18. Nplate(R), (Romiplostim), for Subcutaneous Injection [Prescribing Information] CA: Amgen Inc, Thousand Oaks November 2012 http://pi.amgen.com/ united-states/nplate/nplate-pi-hcp-english.pdf
19. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, et al. J Clin Oncol 2010 28 3 437 444 10.1200/JCO.2009.24.7999 20008626
20. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D, Cancer 2011 117 5 992 1000 10.1002/cncr.25545 20945323
21. Update of an open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes (MDS). Fenaux P, Kantarjian H, Muus P, Lyons RM, Larson RA, Sekeres MA, Becker PS, Jia C, Yang AS, Blood 2011 118 21 2772 (ASH Annual Meeting Abstracts)
22. Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS): results of a randomized, double-blind, placebo(PBO)-controlled study. Giagounidis A, Mufti GJ, Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Kuendgen A, Platzbecker U, Gaidano G, Jedrzejczak W, Hu K, Yang AS, Jun S, Blood 2011 118 21 bstract 117
23. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine. Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J, Leuk Lymphoma 2012 Nov 15 [Epub ahead of print].
24. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, et al. Blood 2000 96 12 3671 3674 11090046
25. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP, Blood 2010 116 17 3163 3170 10.1182/blood-2010-03-274753 20631375
26. The World Health Organization (WHO) classification of the myeloid neoplasms. Vardiman JW, Harris NL, Brunning RD, Blood 2002 100 7 2292 2302 10.1182/blood-2002-04-1199 12239137
27. International scoring system for evaluating prognosis in myelodysplastic syndromes. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al. Blood 1997 89 6 2079 2088 9058730
28. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, et al. Blood 2006 108 2 419 425 10.1182/blood-2005-10-4149 16609072